A man with a slowly progressing, rare mutation-driven form of amyotrophic lateral sclerosis (ALS) has shown improved symptoms and continued working as a physician a year after becoming the first person to receive an antisense oligonucleotide therapy targeting his specific genetic mutation. The RNA-b